Close
Smartlab Europe
Inizio Ignite

Drug Research

A Brand-New Medication For Dystonia Treatment Is Underway

Thousands of musicians now have hope after substantial progress was made in the search for a dystonia cure by a research team in Korea. 1–3% of musicians worldwide suffer from musicians' dystonia, while 5% of all dystonia sufferers are musicians....

First Time, Treatment For Acute ASPS Given The Go-Ahead

Atezolizumab (Tecentriq), a therapy for advanced alveolar soft tissue sarcoma (ASPS), has received FDA approval for the first time for adults and children two years of age and older who have ASPS that has migrated to other regions of...

FDA Drug Nods Dip To 37 In 2022 From 51- A Median Since 2017

The FDA recorded only 37 new drug approvals in 2022, down from an annual average of 51 since 2017. After having to retract its contentious 2021 approval of Biogen's Aduhelm Alzheimer's disease medication, has the FDA grown timid? The incident...

New Technique Reveals Best Care For Breast Cancer Patients

A technique created by Karolinska Institutet researchers should be able to forecast whether a breast cancer patient will benefit from a specific treatment or not. According to a study that was published in PNAS, the cell-based approach has been...

Novel Method To Stop Antibody From Blocking Transplant Cells

Researchers at UCSF have developed a novel, potentially life-saving technique that may prevent antibodies from prompting the immune system to reject specifically tailored therapeutic and transplant cells. It has been particularly difficult to cure rejection caused by antibodies as opposed...

US FDA approves Polarean Imaging’s drug device combination product, Xenoview

Polarean Imaging plc, the medical imaging technology company, announces that the US Food and Drug Administration (FDA) has granted approval for its drug device combination product, Xenoview. Xenoview, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast...

PeptiDream, Merck Enter Peptide Drug Conjugates Pact

PeptiDream Inc., a Japan-based biopharmaceutical company, has entered a new multi-target collaboration and license agreement with Merck & Co, Inc. (known as MSD outside the U.S.) focused on the discovery and development of novel peptide drug conjugates (PDCs). PeptiDream will...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »